An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease

An Exploratory Clinical Study to Evaluate UX-DA001 Injection (Human Midbrain Dopaminergic Progenitor Cells Injection) in Subjects With Idiopathic Parkinson's Disease

This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.

Study Overview

• Status: Active, not recruiting
• Conditions: Parkinson Disease, Idiopathic
• Intervention / Treatment: Biological: UX-DA001

Detailed Description

This study is an open-label, multi-center, dose-escalation and dose-expansion exploratory clinical study to evaluate the safety, tolerability, and potential efficacy of UX-DA001 Injection at different dose levels implanted in subjects with idiopathic PD.

Each subject receives only one dose of UX-DA001 for implantation into the putamen bilaterally using stereotactic neurosurgery under general anesthesia. Safety and tolerability of UX-DA001 and its effect on Parkinson's disease symptoms are assessed for 2 years post-treatment.

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200025
      • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The subjects or their legally acceptable representative understand and comply with the study procedures, agree to participate in the clinical trial, and sign the ICF;
2. Aged between 50-75 years old, male or female;
3. Subjects diagnosed with idiopathic PD, with a medical history of 5-20 years;
4. Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined;
5. Good response to levodopa medications; the LCT shows that the maximum improvement rate of the UPDRS part III score exceeds 30%;
6. The modified H&Y scale of clinical "OFF" period is ≥ Stage 3 and ≤ Stage 4;
7. Taking a stable dosage of anti-PD medications for at least 4 weeks;
8. Good physical condition or stable concomitant diseases;
9. With reliable caregivers who can cooperate to complete the assessment items;
10. Subjects with good compliance.

Exclusion Criteria:

1. PD Subjects in whom previous genetic testing has found a GBA gene mutation or PD Subjects whom the investigator considers unsuitable for participation in this clinical study due to other gene mutations;
2. Subjects with the atypical Parkinson's syndrome or secondary Parkinson's syndrome;
3. Subjects with HIV, HBV, HCV, treponema pallidum (TP) infection, or other active infections;
4. Subjects infected with HTLV, EBV or CMV whose infection renders their blood cells unsuitable for cell product preparation;
5. Subjects with a known hereditary disorder;
6. Subjects with any history of malignancy;
7. Subjects with other serious systemic diseases or functional disorders;
8. Accompanied by other serious central nervous system diseases or serious cognitive and mental disorders;
9. Subjects who are currently receiving or have previously received cell therapy or other medicine effecting safety and efficacy assessement;
10. Subjects whose prior head CT/MRI examinations indicate brain injury, or Subjects with imaging abnormalities in the striatum and other brain regions leading to a significant increase in surgical risk, or Subjects who have previously undergone brain surgery;
11. Subjects with clinically significant abnormal results in coagulation function, or Subjects who have been using anticoagulants for a long time and cannot discontinue use;
12. Subjects with a history of severe allergy or hypersensitivity reactions, or a known history of hypersensitivity, or a history of intolerance to the investigational cellular drug or its excipients;
13. Subjects who have undergone other surgeries within the past six months that the investigator deems may affect this trial, or Subjects who cannot tolerate general anesthesia or stereotactic surgery;
14. Subjects with contraindications to MRI and PET scans;
15. Subjects with a history of alcoholism or drug abuse;
16. Women during pregnancy or lactation;
17. Subjects who have participated in other interventional clinical trials or similar clinical trials within the past 3 months;
18. Subjects with other conditions that are not suitable for participation in the clinical study as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: UX-DA001	Biological: UX-DA001; UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery. Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence and and severity of adverse events (AEs) associated with surgery and/or investigational product	The incidence and and severity of adverse events (AEs) associated with surgery and/or investigational product during the surgical treatment period and the 4-week postoperative observation period. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.	within 4 weeks post surgery
The incidence and severity of AEs/serious adverse events (SAEs)	The incidence and severity of AEs/serious adverse events (SAEs) during the study, including AEs and SAEs during the surgery treatment period, postoperative observation period, and follow-up period. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.	From baseline to 2 years post surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
18F-FP-CIT uptake using positron emission tomography (PET)	Changes in 18F-FP-CIT uptake using positron emission tomography (PET) from baseline.	From baseline to 2 years post surgery
The situation of implantation and overgrowth of transplanted cells using cranial MRI	Volume changes of transplanted cells using cranial magnetic resonance imaging (MRI)	From baseline to 2 years post surgery
Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, part III, from baseline.	Minimum score: 0; Maximum score: 132; Higher scores mean a worse outcome.	From baseline to 2 years post surgery
Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, part II, from baseline.	Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome.	From baseline to 2 years post surgery
Changes in modified modified Hoehn-Yahr (H&Y) scale from baseline	Grade 0~Grade 5, lower grade means a better outcome	From baseline to 2 years post surgery
Changes in daily levodopa equivalent dose (LED) from baseline.		From baseline to 2 years post surgery
Changes in the scores of non-motor symptom scales (NMSS) from baseline.	Minimum score: 0; Maximum score: 960; Higher scores mean a worse outcome.	From baseline to 2 years post surgery

Collaborators and Investigators

• Sponsor: Shanghai UniXell Biotechnology Co., Ltd
• Collaborators: Ruijin Hospital
• Investigators: Principal Investigator: Jun Liu, MD, PhD, Ruijin Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: December 30, 2024
• First Submitted That Met QC Criteria: January 11, 2025
• First Posted (Actual): January 16, 2025

Study Record Updates

• Last Update Posted (Actual): June 11, 2026
• Last Update Submitted That Met QC Criteria: June 9, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: stem cells; Induced pluripotent stem cells; Idiopathic Parkinson´s Disease; autologous iPSC derived mDAPs; Midbrain Dopaminergic Progenitors; mDAPs; iPSC derived product
• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: UX-DA001-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No